EVGN Evogene Ltd. logo

EVGN Evogene Ltd.

Healthcare
$0.69+0.00%OpenMarket Cap: $6.0M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

PEG

P/B

-2.72

P/S

3.34

EV/EBITDA

0.03

DCF Value

$-4.64

FCF Yield

-196.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

30.9%

Operating Margin

-757.2%

Net Margin

-639.4%

ROE

934.8%

ROA

-65.4%

ROIC

-104.9%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$3.9M$-7.8M$
Q4 null$314.0K$-5.3M$
FY null$3.9M$-8.5M$
Q3 null$312.0K$3.9M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$3.50

Target (Median)

$3.50

Target Range

$3.50 - $3.50

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Ravzin Polinaofficer: VP Finance
SellThu Apr 09
Ravzin Polinaofficer: VP Finance
SellThu Apr 09
Ravzin Polinaofficer: VP Finance
SellThu Apr 09
Ravzin Polinaofficer: VP Finance
SellThu Apr 09
RECANATI LEONdirector
SellWed Mar 18

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

IL

Exchange

Beta

1.39

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Peers